Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stephen Lory
Harvard Medical School, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
x-Biotix
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This project aims at creating new classes of diagnostic tools and therapeutic agents to combat efflux-based resistance by a project organized into two phases. First genetically encoded fluorescent sensors activated by binding of antibiotics following their entry into the bacterial cytoplasm will be developed. During the second phase of the project, a screening program, using a library of several hundred billion small molecules, to identify inhibitors targeting different components of efflux pumps will be implemented. The second phase of the project will be conducted with x-Chem (parent company of x-biotix). The goal for x-biotix is to develop a new generation of anti-infectives against Gram negative pathogens, including Pseudomonas aeruginosa, the focus of the current NIH grant.
Genetically-encoded fluorescent RNA sensors for measuring transport of antibiotics into the cytoplasm of Gram-negative pathogens and development of efflux pump inhibitors
Project Narrative The objectives of this project are to provide a solution for a major unmet medical need: treatment of multi-drug resistant Gram-negative pathogens, with a focus on Pseudomonas aeruginosa. A series of novel genetically encoded fluorescent RNA sensors will be developed to detect antibiotic flux in this organism and they will be used as part of a campaign to identify and validate efflux pump inhibitors in a collection of hundreds of billion compounds. If successful, the project will generate new therapeutics for us in combinational therapy with antibiotics previously not effective because of their expulsion from cells by efflux pumps before bactericidal levels can be reached.
Filed on February 23, 2018.
Tell us what you know about Stephen Lory's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Stephen Lory filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Stephen Lory | Harvard Medical School | Conflict of Interest | x-Biotix | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.